Entera Bio Ltd. (ENTX)

Entera Bio Ltd.'s stock price declined by 38.29% over the past six months. Individual investors saw a gain in holdings value in October 2025. The company showed earnings in March 2026. A direct investment led by BVF Partners L.P. was made in April 2026. Entera Bio Ltd. issued its quarterly earnings results in May 2026, reporting ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08).

There is no readily available information indicating demand seasonality for Entera Bio Ltd.'s products or services. The demand for its product candidates, once approved, would likely be driven by medical need and market adoption rather than seasonal fluctuations.

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered macromolecule therapeutics. The company operates in the Healthcare sector and Biotechnology industry, addressing underserved chronic medical conditions with oral mini-tablet peptide or peptide replacement therapies. Its major product candidates include EB613 for osteoporosis, EB612 for hypoparathyroidism, EB618 for obesity and metabolic disorders, and Oral GLP-2 for short bowel syndrome.

Entera Bio Ltd. primarily operates in Israel, with its principal and registered office located in Jerusalem.

Entera Bio Ltd. maintains a news sentiment score of 1.50. Entera Bio reported full-year 2024 financial results and business updates in March 2025. The company announced Q1 2025 financial results and business updates in May 2025. Entera Bio presented positive effects of EB613 at ASBMR 2025 in September 2025. The company presented positive new clinical data from the EB613 Phase 2 trial in October 2025. Entera Bio announced its Q1 2026 corporate priorities and pipeline outlook in January 2026. OPKO Health and Entera Bio expanded their partnership in February 2026. Entera Bio submitted a streamlined Phase 3 protocol in March 2026. The company hosted a Key Opinion Leader Webinar in April 2026. Entera Bio announced Q1 2026 financial results and updates in May 2026.

Entera Bio Ltd. has a diverse ownership structure, with both institutional and individual investors holding significant stakes. Major institutional owners include Knoll Capital Management, LLC, Point72 Asset Management, L.P., and Marshall Wace, Llp. Individual investors hold a substantial 55% stake in Entera Bio.